MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Chiusa

SettoreSettore sanitario

123.73 2.37

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

120.87

Massimo

125.59

Metriche Chiave

By Trading Economics

Entrata

-7.9B

1.3B

Vendite

-616M

10B

P/E

Media del settore

17.147

39.857

EPS

1.09

Rendimento da dividendi

1.74

Margine di Profitto

12.792

Dipendenti

114,000

EBITDA

-324M

2.7B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+21.77% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.74%

2.42%

Utili prossimi

15 ott 2025

Prossima data del Dividendo

15 ago 2025

Prossima data del' Ex Dividendo

14 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

230B

Apertura precedente

121.36

Chiusura precedente

123.73

Notizie sul Sentiment di mercato

By Acuity

41%

59%

138 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Abbott Laboratories Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 12:10 UTC

Utili

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16 apr 2025, 16:21 UTC

Utili

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 apr 2025, 12:14 UTC

Utili

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17 lug 2025, 13:14 UTC

Utili

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 lug 2025, 12:16 UTC

Utili

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 lug 2025, 11:32 UTC

Utili

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 lug 2025, 11:32 UTC

Utili

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 lug 2025, 11:31 UTC

Utili

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Sales $11.14B >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Net $1.78B >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q EPS $1.01 >ABT

17 lug 2025, 09:08 UTC

Azioni calde

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1 lug 2025, 18:41 UTC

Acquisizioni, Fusioni, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16 apr 2025, 15:09 UTC

Discorsi di Mercato

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 apr 2025, 14:17 UTC

Utili

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 apr 2025, 11:34 UTC

Utili

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 apr 2025, 11:33 UTC

Utili

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 apr 2025, 11:32 UTC

Utili

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 apr 2025, 11:32 UTC

Utili

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 apr 2025, 11:31 UTC

Utili

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Reaffirms Full-Yr Guidance

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Sales $10.36B >ABT

16 apr 2025, 11:30 UTC

Utili

Abbott Labs 1Q Net $1.33B >ABT

Confronto tra pari

Modifica del prezzo

Abbott Laboratories Previsione

Obiettivo di Prezzo

By TipRanks

21.77% in crescita

Previsioni per 12 mesi

Media 146.75 USD  21.77%

Alto 159 USD

Basso 137 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Abbott Laboratories - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

14

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

132.82 / 134.43Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

138 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.